The combination of MEDI3622 with anti-human epidermal growth factor receptor 2 (HER2) antibody trastuzumab greatly augmented the production of IFNγ by NK cells against ovarian cancer cell by blocking the shedding of CD16A on NK cells (164). This evidence concerns the gene ERBB2 and ovarian carcinoma.